Summary
Hydrocodone bitartrate (HB) and acetaminophen (APAP) combination products are known to be abused via oral, intranasal, and intravenous self-administration. Benzhydrocodone HCl (KP201) is a prodrug of hydrocodone with limited bioavailability when taken intranasally or intravenously, or taken orally at supratherapeutic doses. This study assessed the abuse liability, relative bioavailability, and safety of KP201/APAP, compared with that of HB/APAP (Norco®), when administered at supratherapeutic oral doses to non-dependent, recreational opioid users. Both KP201/APAP and HB/APAP were generally well tolerated and had similar Drug Liking scores, but KP201/APAP displayed lower peak and cumulative systemic exposure to hydrocodone at high and mid oral doses.
Register to download
Oral Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone
You may also be interested in:
Poster
A Retrospective Analysis of the Effects of Protocol Design on Completion Rates in Outpatient Clinical Trials in Subjects with Schizophrenia or Schizoaffective Disorder
Subject attrition from randomized Schizophrenia trials is a significant problem and has been found in a meta-analysis to be as high as 76%. The…
Fact Sheet
CSF Sampling
PRA understands how cerebrospinal fluid (CSF) sampling benefits our clients’ early phase trials. We regularly conduct CSF sampling to collect key PK…
White Paper
Alzheimer's Disease Research 2018
PRA conducted a survey at the 2018 Alzheimer's Association International Conference in Chicago. Across the board we found that the research community…